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Gastrin-releasing peptide receptor (GRPR) is overexpressed in
human prostate cancer and is being used as a target for molecular
imaging. In this study, we report on the direct comparison of 3
novel GRPR-targeted radiolabeled tracers: Al18F-JMV5132, 68Ga-
JMV5132, and 68Ga-JMV4168 (JMV5132 is NODA-MPAA-βAla-
βAla-[H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2], JMV4168 is
DOTA-βAla-βAla-[H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2],
and NODA-MPAA is 2-[4-(carboxymethyl)-7-{[4-(carboxymethyl)
phenyl]methyl}-1,4,7-triazacyclononan-1-yl]acetic acid). Methods:
The GRPR antagonist JMV594 (H-D-Phe-Gln-Trp-Ala-Val-Gly-
His-Sta-Leu-NH2) was conjugated to NODA-MPAA for labeling
with Al18F. JMV5132 was radiolabeled with 68Ga and 18F, and
JMV4168 was labeled with 68Ga for comparison. The inhibitory con-
centration of 50% values for binding GRPR of JMV4168, JMV5132,
natGa-JMV4168, and natGa-JMV5132 were determined in a competi-
tion-binding assay using GRPR-overexpressing PC-3 tumors. The
tumor-targeting characteristics of the compounds were assessed
in mice bearing subcutaneous PC-3 xenografts. Small-animal
PET/CT images were acquired, and tracer biodistribution was de-
termined by ex vivo measurements. Results: JMV5132 was labeled
with 18F in a novel 1-pot, 1-step procedure within 20 min, without
need for further purification and resulting in a specific activity of 35
MBq/nmol. Inhibitory concentration of 50% values (in nM) for GRPR
binding of JMV5132, JMV4168, natGa-JMV5132, natGa-JMV4168,
and AlnatF-JMV5132 were 6.8 (95% confidence intervals [CIs],
4.6–10.0), 13.2 (95% CIs, 5.9–29.3), 3.0 (95% CIs, 1.5–6.0), 3.2
(95% CIs, 1.8–5.9), and 10.0 (95% CIs, 6.3–16.0), respectively. In
mice with subcutaneous PC-3 xenografts, all tracers cleared rapidly
from the blood, exclusively via the kidneys for 68Ga-JMV4168 and
partially hepatobiliary for 68Ga-JMV5132 and Al18F-JMV5132. Two
hours after injection, the uptake of 68Ga-JMV4168, 68Ga-JMV5132,
and Al18F-JMV5132 in PC-3 tumors was 5.96 ± 1.39, 5.24 ± 0.29,
5.30 ± 0.98 (percentage injected dose per gram), respectively. GRPR
specificity was confirmed by significantly reduced tumor uptake of
the 3 tracers after coinjection of a 100-fold excess of unlabeled
JMV4168 or JMV5132. Small-animal PET/CT clearly visualized PC-
3 tumors, with the highest resolution observed for Al18F-JMV5132.
Conclusion: JMV5132 could be rapidly and efficiently labeled with
18F. Al18F-JMV5132, 68Ga-JMV5132, and 68Ga-JMV4168 all showed
comparable high and specific accumulation in GRPR-positive PC-3
tumors. These new PET tracers are promising candidates for future
clinical translation.
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Prostate cancer (PCa) is the most frequently diagnosed cancer
and the second leading cause of cancer death among men in the
United States (1). There is a strong need for improved imaging
techniques that provide accurate staging and monitoring of this
disease, particularly at early stages. Conventional diagnostic tech-
niques, such as ultrasound-guided biopsy, are limited by high
false-negative rates (2). Emerging functional imaging techniques,
including diffusion-weighted MR imaging, dynamic contrast-
enhanced MR imaging, and PET, have shown improved sensitivity
and staging accuracy for detecting primary prostate tumors and
metastatic lymph nodes (3). Several PET radiotracers have shown
promising clinical utility, such as the metabolic agents 18F-FDG,
11C-/18F-choline, and 11C-/18F-acetate for the assessment of dis-
tant metastasis and 18F-NaF for the detection of bone metastasis (4).
However, their application is most valuable in late-stage, recurrent,
or metastatic PCa. Increasing efforts are being made in developing
PET imaging agents targeting specific biomarkers of PCa, such as
gastrin-releasing peptide receptor (GRPR) (5) and prostate-specific
membrane antigen (6).
The GRPR, or bombesin (BBN) receptor subtype II, has been
shown to be overexpressed in several human tumors, including
PCa (7). Overexpression of GRPR was found in 63%–100% of
primary prostate tumors and more than 50% of lymph and bone
metastases (8,9). The GRPR density was reported to be 26-fold
higher in prostate carcinoma than prostatic hyperplasia (9). Be-
cause of the low expression in benign prostatic hyperplasia and
inflammatory prostatic tissues, imaging of GRPR in localized PCa
has potential advantages over choline- and acetate-based radio-
tracers (9,10).
A variety of radiolabeled BBN analogs have been developed for
targeting GRPR-positive tumors and were evaluated in preclinical
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and clinical studies (5). Several recent reports have shown that
GRPR antagonists show properties superior to GRPR agonists,
affording higher tumor uptake and lower accumulation in physio-
logic GRPR-positive nontarget tissues (11,12). Moreover, GRPR
agonists were shown to induce side effects in patients, mediated
by virtue of their physiologic activity (13,14). Therefore, particu-
lar attention has been drawn to the development of GRPR antag-
onists for imaging and radionuclide therapy of PCa. Several
GRPR antagonists have since been developed by the modification
of C-terminal residues of GRPR agonists, including the statin-
based BBN analog, JMV594 (H-D-Phe-Gln-Trp-Ala-Val-Gly-
His-Sta-Leu-NH2) (15).
68Ga-labeled GRPR antagonists were developed for PET
imaging, showing good targeting properties in preclinical studies
(12,16–18) and recently also in clinical trials (19,20). Clinical
evaluation of the 68Ga-labeled GRPR antagonist BAY86-7548
(68Ga-DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-
Ala-Val-Gly-His-Sta-Leu-NH2) has shown a specificity, sensitiv-
ity, and accuracy of 88%, 81%, and 83%, respectively, for the
detection of primary PCa. In comparison, it was shown that 11C-
choline was not able to discriminate PCa from benign prostatic
hyperplasia, because maximum standardized uptake values in PCa
were not significantly different from benign prostatic hyperplasia
(21). Another study reported a specificity, sensitivity, and accuracy
of 80%, 29%, and 71%, respectively, for the detection of PCa
using 11C-choline (22). The detection of lymph node metastases
with the 68Ga-labeled GRPR antagonist was suboptimal, partially
due to the suboptimal physical characteristics of 68Ga, limiting the
detection of small lesions (20). Therefore, the aim of the present
study was to develop an 18F-labeled GRPR antagonist for high-
resolution and sensitive PET imaging of primary, recurrent, and
metastatic PCa and to compare the imaging properties of this
tracer with those of 68Ga-labeled analogs. 18F has superior phys-
ical characteristics for PET imaging, such as a lower positron
range and a higher positron yield, offering higher resolution and
sensitivity (23). However, most methods for labeling peptides with
18F are laborious and require multistep procedures with moderate
labeling yields. A good alternative is the Al18F-labeling method
(24), allowing fast and facile labeling of peptides in a 1-step pro-
cedure. We designed a new GRPR antagonist conjugate (JMV5132
[NODA-MPAA-bAla-bAla-(H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-
Leu-NH2); NODA-MPAA is 2-(4-(carboxymethyl)-7-{[4-(carboxy-
methyl)phenyl]methyl}-1,4,7-triazacyclononan-1-yl)acetic acid]),
analogous to the previously described JMV4168 (DOTA-bAla-
bAla-[H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2]) (25), with
a NODA-MPAA chelator for high-yield complexation of Al18F
(26). Here, we report on the direct preclinical comparison of 3 novel
radiolabeled tracers (Al18F-JMV5132, 68Ga-JMV4168, and 68Ga-
JMV5132) for PET imaging of PCa. We determined the in vitro
characteristics of the radiolabeled peptides and evaluated their
tumor targeting properties in vivo in nude mice with subcutaneous
human prostate tumors.
MATERIALS AND METHODS
Synthesis of JMV4168 and JMV5132
JMV4168 was synthesized using Fmoc-based solid-phase peptide
synthesis as described previously (25). JMV5132 was synthesized in the
same manner as JMV4168 but was coupled to tert-butyl (tBu)–protected
NODA-MPAA instead of tBu-protected DOTA. NODA-MPAAwas pre-
pared as previously described using NO2AtBu (Chematech) (26). The
chemical structures of JMV4168 and JMV5132 are shown in Figure 1.
Radiolabeling
Radiolabeling of JMV5132 with Al18F. 18F2 solution in enriched
water (BV Cyclotron, VU) was purified from metal impurities and con-
centrated before use, as described in the supplemental materials (avail-
able at http://jnm.snmjournals.org). Labeling was performed by mixing
18F2 solution (15–20 mL, 700–900 MBq), sodium acetate (NaOAc) (0.5
mL of 1 M solution, pH 4.1), Al31 stock solution (20 nmol, 10 mL of 2
mM AlCl36H2O in 0.1 M NaOAc, pH 4.2), acetonitrile (67% v/v),
quenchers (2.5 mL of 50 mM methionine, gentisic acid, and ascorbic
acid), and finally JMV5132 (20 nmol, 3.26 mL of solution [10 mg/mL] in
2 mM NaOAc, pH 4.1). The reaction mixture was heated for 15 min at
105C. To allow injection into mice, the peptide was diluted to less than
0.5% (v/v) acetonitrile with 0.5% (w/v) bovine serum albumin, 0.5%
(w/v) polyoxyethylene (20) sorbitan monolaurate solution (polysorbate-
20), and quenchers (1 mM methionine, gentisic acid, and ascorbic acid)
in phosphate-buffered saline (PBS), pH 7.4. Bovine serum albumin and
polysorbate-20 were added to reduce binding of radiolabeled peptide to
plastic disposables, whereas quenchers (methionine, gentisic acid, and
ascorbic acid) were added to prevent radiolysis of radiolabeled peptides.
Radiolabeling of JMV4168 and JMV5132 with 68Ga. Elution and
purification of 68Ga from a 68Ga/68Ge generator (IGG-100; Eckert &
Ziegler Europe) was performed using the sodium chloride–based pro-
cedure described earlier (27). Avolume of 375 mL of 4-(2-hydroxyethyl)
piperazine-1-ethanesulfonic acid (1 M, pH 3.6) was slowly added to
300 mL of purified 68Ga eluate, followed by addition of quenchers
(methionine, gentisic acid, and ascorbic acid,
1.25 mM) and peptide (2 nmol). The reaction
mixture was heated for 10 min at 95C. After
reaction, ethylenediaminetetraacetic acid (50
mM) was added to a final concentration of 5
mM to complex free 68Ga. For animal experi-
ments, the labeled product was purified by
reversed-phase high-performance liquid chro-
matography (RP-HPLC) using the gradient
described in the “Quality Control” section of
the supplemental materials and concentrated by
evaporation. To allow injection into mice, the
radiolabeled peptide was diluted with 0.5%
(w/v) bovine serum albumin, 0.5% (w/v)
polysorbate-20, and quenchers (1 mM methi-
onine, gentisic acid, and ascorbic acid) in
PBS and neutralized with sodium carbon-
ate (NaHCO3) buffer (1 M, pH 8.5).
FIGURE 1. Chemical structures of DOTA-βAla-βAla-[H-D-Phe-Gln-Trp-Ala-Val-Gly-His-
Sta-Leu-NH2] (JMV4168) (A) and NODA-MPAA-βAla-βAla-[H-D-Phe-Gln-Trp-Ala-Val-Gly-
His-Sta-Leu-NH2] (JMV5132) (B).
18F-LABELED GRPR ANTAGONIST • Chatalic et al. 2051
by on March 1, 2017. For personal use only. jnm.snmjournals.org Downloaded from 
Cold Labeling of JMV4168 and JMV5132 with natGa and natF. The
labeling methods of JMV4168 and JMV5132 with natGa and natF are
described in the supplemental materials.
Quality Control
Quality control methods for peptide synthesis and radiolabeling are
described in detail in the supplemental materials.
Lipophilicity. The octanol/PBS partition coefficients of 68Ga-
JMV4168, 68Ga-JMV5132, and Al18F-JMV5132 were determined as de-
scribed previously (28).
Cell Culture and Competitive Cell Binding Assay
The human PCa cell line PC-3 was cultured in Ham F-12K (Kaighn’s)
medium (Life Technologies) supplemented with 10% fetal calf serum,
penicillin (100 units/mL), and streptomycin (100 mg/mL). Cells were
grown in tissue culture flasks at 37C in a humidified atmosphere
containing 5% CO2.
The binding affinities of JMV4168, JMV5132, natGa-JMV4168,
natGa-JMV5132, and AlnatF-JMV5132 toward the GRPR were deter-
mined in a competitive binding assay using frozen cryostat sections (10-
mm thick) of PC-3 xenografts and [125I-Tyr4]-BBN as a tracer. Tyr4-BBN
(Sigma Aldrich) was iodinated as described earlier (29). The compet-
itive binding assay protocol is described in detail in the supplemental
materials.
Small-Animal PET/CT and Biodistribution Studies
Male nude BALB/c mice (age, 6–8 wk) were injected subcutaneously
near the right shoulder with a PC-3 cell suspension (5 · 106 cells, 200
mL, 66% RPMI, 33% Matrigel [BD Biosciences]). Two to 3 wk after
inoculation, when tumor size averaged 200 mm3, mice were injected
intravenously with 5–10 MBq of radiolabeled peptide (200 pmol, 200
mL). To confirm the receptor specificity of the radiolabeled peptides,
additional animals were coinjected with an excess (20 nmol) of unla-
beled peptide. Mice were euthanized 1 or 2 h after injection by CO2/O2
asphyxiation. Mice were first scanned prone on a small-animal PET/CT
scanner (Inveon; Siemens Preclinical Solutions). PET emission scans
were acquired for 30–60 min, followed by
a CT scan. After scanning, blood, tumor, and
relevant organs and tissues were collected,
weighed, and counted in a g counter. Scanning
and reconstruction parameters, as well as
counting parameters, are described in detail
in the supplemental materials. The percentage
injected dose per gram (%ID/g) was deter-
mined for each tissue sample. All animal
experiments were approved by local authori-
ties and were in compliance with the institu-
tions guidelines.
Statistical Analysis
Statistical analysis was performed using
GraphPad Prism (version 5.01; GraphPad
Software) and described in the supplemental
materials.
RESULTS
Synthesis of JMV4168 and JMV5132
JMV4168 and JMV5132 (Fig. 1) were
obtained with an average yield of approxi-
mately 40% and a purity greater than 97% as
confirmed by RP-HPLC. Conjugates were
characterized by electrospray ionization mass
spectroscopy (mass/charge, [M12H]21/2:
JMV4168, calculated: 815.9414, found: 815.9412; JMV5132, calculated:
821.4416, found: 821.4433).
Radiolabeling and Stability Studies
Al18F-JMV5132 was obtained with a specific activity of 40 6
4 MBq/nmol (88% non–decay-corrected yield) and 68Ga-JMV4168
and 68Ga-JMV5132 with a specific activity of 47 6 2 and 47 6 4
MBq/nmol after purification, respectively. RP-HPLC analysis in-
dicated that the radiochemical purity of the Al18F- or 68Ga-labeled
peptide preparations used in in vitro and in vivo experiments al-
ways exceeded 95%. Radio-HPLC elution profiles of Al18F- and
68Ga-labeled peptides are shown in Figure 2A. 68Ga-JMV4168,
68Ga-JMV5132, and Al18F-JMV5132 had retention times of 13.8,
19.6, and 21.9 min, respectively. The addition of quenchers (methi-
onine, gentisic acid, and ascorbic acid) prevented oxidation of the
radiolabeled peptides, as shown in Figure 2B.
Lipophilicity
The octanol/PBS partition coefficients were determined to
estimate the lipophilicity of the Al18F- or 68Ga-labeled peptides.
The log Poctanol/PBS values for 68Ga-JMV4168, 68Ga-JMV5132,
and Al18F-JMV5132 were 22.53 6 0.04, 21.40 6 0.01, and
21.566 0.08, respectively. This result shows that the 68Ga-DOTA
analog (JMV4168) was more hydrophilic than the 68Ga- and
18F-NODA-MPAA analogs (JMV5132).
Competitive Cell Binding Assay
The affinity of JMV4168, JMV5132, natGa-JMV4168, natGa-
JMV5132, and AlnatF-JMV5132 for the GRPR was determined
in a competitive binding assay, using [125I-Tyr4]-BBN as radioli-
gand. The displacement binding curves are shown in Figure 3.
Inhibitory concentration of 50% (IC50) values (in nM) for binding
to GRPR for JMV5132 (NODA-MPAA), JMV4168 (DOTA), and
AlnatF-JMV5132 were not significantly different: 6.8 (95%
FIGURE 2. Radio–high-performance liquid chromatograms of 68Ga-JMV4168 (A), 68Ga-JMV5132
(B), and Al18F-JMV5132 (C). (D) Radio–high-performance liquid chromatogram of 68Ga-JMV5132
without added quenchers. y-axis 5 radioactivity in count per second (cps); x-axis 5 retention time
in min. EDTA 5 ethylenediaminetetraacetic acid; tR 5 retention time.
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confidence interval [CI], 4.6–10.0), 13.2 (95% CI, 5.9–29.3), and
10.0 nM (95% CI, 6.3–16.0), respectively. IC50 values for natGa-
JMV5132 (3.0 [95% CI, 1.5–6.0]) and natGa-JMV4168 (3.2 [95%
CI, 1.8–5.9]) were lower than their unlabeled counterpart, indicat-
ing a higher binding affinity for the GRPR.
Small-Animal PET/CT and Biodistribution Studies
Fused PET and CT images obtained at 1 and 2 h after
injection are shown in Figure 4. Maximum-intensity projections
showed clear visualization of PC-3 tumors with very low back-
ground. Predominant renal excretion was observed for all 3
radiolabeled peptides. Partial hepatobiliary excretion was ob-
served for Al18F-JMV5132 and 68Ga-JMV5132, as indicated
by the nonspecific uptake in the gallbladder and intestines.
PET images obtained at 2 h after injection showed partial clear-
ance of radioactivity in nontarget tissues such as pancreas, kid-
ney, and intestines as compared with the images obtained at 1 h
after injection.
The results of the biodistribution studies of 18F- and 68Ga-
labeled peptides are summarized in Figure 5. These pharmacokinetic
data obtained at 1 and 2 h after injection were in line with the PET
images. High and specific uptake of the tracer was observed in the
PC-3 tumors. There were no significant differences for 68Ga-
JMV4168, 68Ga-JMV5132, and Al18F-JMV5132, with uptake val-
ues (in %ID/g) of 4.46 6 0.33, 4.73 6 0.68, and 4.96 6 1.20,
respectively, at 1 h after injection and 5.96 6 1.39, 5.24 6 0.29,
and 5.30 6 0.98, respectively, at 2 h after injection. The uptake in
GRPR-positive organs, such as tumor, pancreas, stomach, and
intestines, was significantly decreased by coinjection of an excess
of unlabeled peptide, indicating GRPR-specific targeting. All trac-
ers displayed fast blood clearance, with 0.09 6 0.04, 0.19 6 0.13,
and 0.05 6 0.01 %ID/g remaining in blood at 2 h after injection
for 68Ga-JMV4168, 68Ga-JMV5132, and Al18F-JMV5132, respec-
tively. The 3 tracers cleared rapidly from the GRPR-positive pan-
creas between 1 h (6.14 6 0.68, 11.42 6 0.84, and 4.21 6 1.34
%ID/g) and 2 h after injection (1.00 6 0.24, 1.33 6 0.25, and
1.41 6 0.15 %ID/g) for 68Ga-JMV4168, 68Ga-JMV5132, and
Al18F-JMV5132, respectively, whereas PC-3 tumor uptake was pre-
served. The uptake and retention of all tracers in blood, muscle,
FIGURE 3. Competition binding curves. PC-3 frozen sections were
incubated in presence of 5.10−10 M [125I-Tyr4]-BBN and increasing
amounts of JMV4168, JMV5132, natGa-JMV4168, or natGa-JMV5132.
IC50 values (with 95% CIs in parentheses) were 6.8 nM (4.6–10.0) for
JMV5132, 13.2 nM (5.9–29.3) for JMV4168, 3.0 nM (1.5–6.0) for natGa-
JMV5132, 3.2 nM (1.8–5.9) for natGa-JMV4168, and 10.0 nM (6.3–16.0)
for AlnatF-JMV5132.
FIGURE 4. PET/CT images of mice bearing subcutaneous PC-3 xeno-
grafts on right shoulder (arrow) injected with 68Ga-JMV4168 (left), 68Ga-
JMV5132 (center), or Al18F-JMV5132 (right) at 1 h after injection (A), 2 h
after injection (B), and 2 h after injection with coinjection of excess un-
labeled peptide (C). Besides tumor (arrow), pancreas, intestines, and
kidneys can be observed in abdominal region. Bladder can be distin-
guished by hot spot below abdomen. Gallbladder can be recognized as
hot spot below rib cage.
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heart, lung, liver, and bone were relatively low as measured at 2 h
after injection (all #0.5 %ID/g). Mice injected with Al18F-
JMV5132 showed a (significantly) higher uptake in spleen and
bone.
DISCUSSION
The use of radiolabeled GRPR antagonists for targeting tumors
in vivo has attracted considerable attention, starting with somato-
statin receptor antagonists showing higher tumor uptake and
targeting more receptor-binding sites than their agonists (30). This
finding was also extended to GRPR antagonists, with the seminal
work of Cescato et al. (11). Recently, more articles have appeared
showing the promise of novel radiolabeled GRPR antagonists for
GRPR-positive tumor imaging (12,16–18,25). The studies revealed
favorable pharmacokinetics of radiolabeled antagonists, including
high tumor uptake and fast clearance from nontargeted tissues.
Several 64Cu- and 68Ga-labeled receptor antagonists developed for
PET imaging of prostate tumors have shown pharmacokinetics su-
perior to 64Cu- or 18F-labeled GRPR agonists described in earlier
literature (12,16,17). Besides a favorable pharmacokinetic profile,
the use of antagonists should reduce the occurrence of side effects.
In a study in which BBN was infused intravenously in a dose of
15 ng/kg/min over a 90-min period, side effects—among which
were nausea, hot flush, and sweating—were observed in 80% of
the patients (13).
Here, we report on the development of a NODA-MPAA–
conjugated GRPR antagonist (JMV5132) labeled with 18F for PET
imaging of GRPR-positive tumors and the direct comparison with
68Ga-radiolabeled analogs. In our previous work, the statin-based
GRPR antagonist JMV594 was linked to DOTA via a (bAla)2 linker
and labeled with 111In. It showed good tumor targeting in PC-3
xenografts in mice (25). In the present study,
we conjugated JMV594 to NODA-MPAA
for radiolabeling with 18F. The NODA-
MPAA-(bAla)2-JMV594 peptide (JMV5132)
was labeled with 18F and 68Ga and com-
pared with the 68Ga-labeled DOTA-(bAla)2-
JMV594 peptide (JMV4168).
The radiolabeling of peptides via com-
plexation of Al18F by a NOTA chelator
was first described by McBride et al.
(24). This novel technique has been suc-
cessfully applied to several peptides, in-
cluding a GRPR agonist (28) and recently
to GRPR antagonists (31,32). Recently,
McBride et al. reported the labeling of pep-
tides with Al18F in a 1-pot, 1-step proce-
dure using the NODA-MPAA chelator (26,
33), leading to a kit formulation, after
which the labeled peptide could be purified
by solid-phase extraction.
In the present study, we further opti-
mized the labeling conditions to achieve
Al18F-labeled JMV5132 in less than
20 min with complete incorporation of
18F-fluoride, resulting in a high specific ac-
tivity (35 MBq/nmol), without the need for
purification by solid-phase extraction. In
receptor-binding studies using PC-3 tumor
sections, the in vitro affinities of JMV5132
and JMV4168 were comparable, as shown by the similar IC50
values, indicating that both chelators apparently affected receptor
affinity in a similar way. The peptides labeled with natGa had
slightly higher receptor affinities than their unlabeled counterpart,
indicating that the presence of Ga31 in the chelator enhanced the
affinity of the peptides for the GRPR. The affinity of the peptide
labeled with natAlF, on the other hand, was not significantly differ-
ent from its unlabeled counterpart, indicating that the presence of
AlF in the chelator did not affect the affinity of the peptide for the
GRPR.
The PET images obtained with Al18F-JMV5132 showed higher
spatial resolution than the images obtained with the 68Ga-labeled
tracers, which is most likely due to the longer positron range of
68Ga (34) as compared with 18F.
The comparative biodistribution study showed GRPR-specific
accumulation of all 3 radiolabeled GRPR antagonists in the
tumor. 68Ga-JMV4168, 68Ga-JMV5132, and Al18F-JMV5132 tracers
showed similar uptake in the GRPR-positive tumor and organs, including
PC-3 tumor, pancreas, stomach, and colon. The uptake was receptor-
mediated, as confirmed by the reduction of uptake in tumor and
other receptor-positive organs after coinjection of excess unla-
beled peptide. The washout from receptor-positive organs occurred
at different rates. The pancreas uptake decreased from 1 to 2 h after
injection by a factor of 6.1, 8.6, and 3.0 for 68Ga-JMV4168, 68Ga-
JMV5132, and Al18F-JMV5132, respectively, whereas tumor uptake
was increased by a factor of 1.3, 1.1, and 1.1 for 68Ga-JMV4168,
68Ga-JMV5132, and Al18F-JMV5132, respectively. This outcome
indicates a higher retention of the tracers in the tumor than in the
pancreas.
Despite their low internalization rate, the high and persistent
tumor uptake of these radiolabeled antagonists was expected,
as it was previously described for a few other radiolabeled
FIGURE 5. Biodistribution of 68Ga-JMV4168 (red), 68Ga-JMV5132 (blue), and Al18F-JMV5132
(green) in mice bearing PC-3 xenografts at 1 h after injection (A), 2 h after injection (B), and 2 h
after injection with coinjection of excess unlabeled peptide (C) and tumor-to-organ ratios at 2 h
after injection (D). Int 5 intestines.
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antagonists (11,12,16,18). This might be explained by a higher
number of binding sites for receptor antagonists than agonists,
a higher metabolic stability of antagonists, or a strong interac-
tion of the antagonist with the receptor (11,16). In previous
studies using radiolabeled GRPR antagonists, a faster clearance
from the pancreas and abdominal organs was already observed
between 1 and 4 h after injection, in contrast with data concern-
ing radiolabeled GRPR agonists, which showed more sustained
retention of activity in the abdominal region. Several reasons
for these differences in tissue clearance kinetics have been postu-
lated, including species differences or more efficient perfusion in
the pancreas and intestine (16). Possible metabolic degradation of
the peptide by enzymes in the pancreas might also explain the
faster washout from the pancreas.
Clearance from background tissues, such as blood, muscle,
heart, lung, liver, and bone, was fast for all tracers tested, leading
to high tumor-to-background ratios, which allowed clear visual-
ization of the tumor. Overall, Al18F-JMV5132 showed improved
imaging properties, compared with the previously reported Al18F-
NOTA-8-Aoc-BBN(7-14)NH2 GRPR agonist (28), because that
analog showed lower tumor uptake, much higher pancreatic up-
take, and higher liver and intestinal uptake in the same animal
model.
The slightly higher uptake of Al18F-JMV5132 in bone may be
due to the presence of trace amounts (,1%) of uncomplexed
Al18F or 18F-fluoride or partial defluorination of the tracer in vivo.
The uptake of Al18F-JMV5132 in bone was relatively low (0.52 6
0.13 %ID/g 2 h after injection), in comparison with the values
reported for the Al18F-labeled RM1 derivative (1.58 %ID/g 2 h
after injection) (31). The increased uptake of Al18F-JMV5132 and
68Ga-JMV5132 in the gallbladder, liver, and gastrointestinal
excretions indicates partial hepatobiliary excretion of the tracers,
because of their higher lipophilicity, which may be caused by the
benzyl group. Considering the clinical application of the tracers,
high signal intensity in the intestines may affect visualization of
prostate-confined tumor or spread to lymph nodes. Nevertheless,
considering the superior imaging characteristics of 18F, further
development of Al18F-JMV5132 as a tracer for PCa diagnostic
and therapy follow-up is certainly warranted.
CONCLUSION
Highly sensitive and receptor-specific imaging of PCa with
PET/CT can be achieved using 68Ga- and 18F-labeled GRPR
antagonists. In this study, labeling of JMV5132 with Al18F was
completed within 20 min with high specific activity without a need
for purification. The 68Ga-JMV4168 tracer showed the most favor-
able biodistribution, because of its lower hepatobiliary excretion,
but the PET images showed a higher resolution with the 18F-
JMV5132 tracer. These new PET tracers are promising candidates
for future clinical translation.
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